Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

NCT00039780 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

764

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms
Breast Diseases
Metastases, Neoplasm

Interventions

DRUG: BNP7787
DRUG: Placebo

Sponsor

BioNumerik Pharmaceuticals, Inc.

Collaborators

[object Object]